In Vitro Design of Preclinical Models for Chemotherapy Combinations in Human Breast Tumours
Journal Title: Journal of Clinical and Diagnostic Research - Year 2019, Vol 13, Issue 5
Abstract
ABSTRACT Introduction: Globally, breast cancer persists a main cause of mortality. Because the number of possible drug combinations is basically unlimited, a strategy for the design of combination chemotherapy regimen of two anti-breast cancer drugs and determining the most promising combinations is crucial for improving the therapeutic outcomes and overcome the multi-therapeutic approach and holds the promise of delivering therapy to those in need. Aim: To assess the activity of combination of Doxorubicin and 5-fluorouracil on Human Breast Cancer Cell line (MCF-7). Materials and Methods: The cytotoxicity of Doxorubicin (DOX) and 5 fluorouracil (5FU) drugs or their combinations were evaluated by using 3-(4,5-Dimethylthiazol-2-yl)-2, 5 Diphenyltetrazolium Bromide (MTT) viability assay against human breast cancer cell line MCF-7. Then, the combination effect proposed by Chou TC et al., based on IC50 values obtained from drugs alone and their combination was evaluated by Combination Index (CI) to determine the nature of synergism, antagonism and additivity action of drug combinations as: synergistic effect is recorded if CI <1, additive effect if CI=1, or antagonism if CI >1, the median-effect dose (Dm) also studied. Dose-Reduction Index (DRI) was also calculated to indicate the level of dose reduction for each drug in synergistic combination. Experiments were achieved with triplicate samples. The MTT assay data were expressed as mean±Standard Deviation (SD). The IC50 values for each drug were computed by GraphPad Prism 5.2 software (GraphPad Software Inc., USA). Dose-effect curve parameters, CI values, Fa-CI, DRI-Faplot were calculated by CompuSyn program. Results: The proliferation of MCF-7 cells was inhibited by 5 FU and DOX anti-cancer drugs in a dose-dependent effect. The DOX at (0.1) nM was antagonistic according to CI value which was 2.82283, while at (1) nM, the CI was 0.39429 that indicate strong synergistic action. Conclusion: This study confirmed the favourable effect of 5 FU in combination with DOX for treatment of breast cancer cell MCF-7 better than the single drug treatment.
Authors and Affiliations
Randa Mohammed Dhahi
Keywords
Related Articles
- EP ID EP585866
- DOI 10.7860/JCDR/2019/40273.12859
- Views 86
- Downloads 0
HER2 and Helicobacter pylori Status in Resected Gastric Cancers: A Pathological Study of a Gastroenterological Issue
Introduction: Human epidermal growth factor receptor 2 (HER2)/neu is a critical target for gastric carcinoma treatment utilizing trastuzumab. Helicobacter pylori is a well known causative agent of gastric carcinoma. Aim:...
Use of Dexmedetomidine in Patients Undergoing Craniotomies
Introduction: The neuroanaesthesia ensures stable perioperative cerebral haemodynamics, avoids sudden rise in intracranial pressure and prevents acute brain swelling. The clinical characteristics of dexmeditomidine make...
Fraternal Twin Tumours of the Oesophagus and Stomach Presenting in the Advanced Stage – A Rare Case with a Fatal End
Synchronous primary tumours of the aerodigestive tract presenting with different histologies is a very rare event. A case with such an association is presented here. A 50-year-old lady presented with symptoms of abdomina...
Effects of Organophosphorus Pesticides on Cardiorespiratory Parameters among the Farmers
Introduction: Indiscriminate use and improper handling of synthetic pesticides in agriculture have resulted in serious problems such as asthma, wheeze and chronic bronchitis among the farmers. Though number of studies ha...
Assessment of Common Risk Factors Between Oral Diseases and Non-communicable Diseases in a Hospital-based Population in Kerala, India- A Cross-sectional Study
ABSTRACT Introduction: Non-Communicable Diseases (NCDs) have assumed epidemic proportions around the world. Oral diseases also pose tremendous physical and emotional burden on the people. Both these conditions (NCDs and...